Can you survive long-term while taking giritinib?

Whether long-term survival can be achieved after taking giritinib is a complex issue because it involves multiple factors, including the patient's specific illness, physical condition, response to the drug, and whether the patient received treatment in a timely manner. As a targeted drug targeting FLT3 mutations, giritinib has shown significant therapeutic effects in the treatment of specific types of leukemia, especially acute myeloid leukemia (AML).

1.Significantly prolong survival: According to clinical trial data, giritinib can significantly prolong the survival of FLT3 mutated AML patients. For example, in a study involving patients with relapsed or refractory FLT3mutationsAML3 In the phase 1 trial, the median overall survival of the patient group who received giritinib was 9.3 months, which was significantly longer than the 5.6 months of the patient group who received salvage chemotherapy. This suggests that giritinib has a positive effect on prolonging patient survival.

2.High response rate: Giritinib also showed a high response rate. In the above-mentioned clinical trials, the proportion of patients who achieved complete remission in the gilitinib group was higher than that in the chemotherapy group. This means that more patients can achieve significant remission under treatment with giritinib, thereby potentially achieving longer survival.

3.The impact of individual differences: However, it is important to note that each patient’s response and survival are different. Factors such as the patient's constitution, severity of illness, response to drugs, and timely treatment will all affect survival. Therefore, although giritinib has shown significant efficacy in clinical trials, it does not guarantee that every patient will achieve long-term survival.

4.Continuous treatment and maintenance of remission: Continuous treatment with giritinib is crucial to maintain remission and prolong survival. Some patients achieve long-term remission after maintenance treatment with giritinib. However, this also requires patients to actively cooperate with treatment and follow the doctor's recommendations.